We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+11.1%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$440M
AUM Growth
+$9.07M
Cap. Flow
-$6.96M
Cap. Flow %
-1.58%
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$10.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$5.13M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.36M
4
BCAX
Bicara Therapeutics
BCAX
+$2.76M
5
FULC icon
Fulcrum Therapeutics
FULC
+$1.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$9.76M
2
AXGN icon
Axogen
AXGN
+$7.38M
3
ATXS
Astria Therapeutics
ATXS
+$3.99M
4
RVMD icon
Revolution Medicines
RVMD
+$2.41M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
76
Foghorn Therapeutics
FHTX
$372M
$535K 0.12%
111,859
-15,000
-12% -$82.3K
IBIO icon
77
iBio
IBIO
$71M
$368K 0.08%
+193,638
New +$449K
BCYC
78
Bicycle Therapeutics
BCYC
$273M
$299K 0.07%
64,492
– –
ADCT icon
79
ADC Therapeutics
ADCT
$128M
$270K 0.06%
72,081
-5,000
-6% -$19.7K
KPTI icon
80
Karyopharm Therapeutics
KPTI
$45.8M
$255K 0.06%
45,800
-5,200
-10% -$39.6K
AUTL
81
Autolus Therapeutics
AUTL
$572M
$247K 0.06%
179,316
– –
NMRA icon
82
Neumora Therapeutics
NMRA
$296M
$137K 0.03%
+70,000
New +$181K
ATXS
83
DELISTED
Astria Therapeutics
ATXS
– –
-304,775
Closed -$3.99M
BWAY
84
Brainsway
BWAY
$655M
– –
-25,930
Closed -$247K
CATX icon
85
Perspective Therapeutics
CATX
$365M
– –
-50,000
Closed -$138K
ERAS icon
86
Erasca
ERAS
$6.43B
– –
-254,436
Closed -$947K
1 2 3
4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, DAFNA Capital Management held 87 positions worth $440M, up 2.1% from $431M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2026 filing shows 10 new, 20 increased, 29 reduced and 4 closed positions. Its largest new stake was Fulcrum Therapeutics: 205,000 shares worth $1.57M. The largest sale was Cytokinetics, an estimated $9.76M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2026 buy was Fulcrum Therapeutics: 205,000 shares worth $1.57M.
  • DAFNA Capital Management added most to Compass Pathways in Q1 2026, an estimated $10.8M increase.
  • DAFNA Capital Management's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $9.76M.
  • DAFNA Capital Management fully exited Astria Therapeutics in Q1 2026, selling an estimated $3.99M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $440M portfolio in Q1 2026.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q1 2026.
  • DAFNA Capital Management's portfolio value rose 2.1% quarter-over-quarter to $440M.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.